These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22824487)

  • 1. Prediction of heparin binding sites in bone morphogenetic proteins (BMPs).
    Gandhi NS; Mancera RL
    Biochim Biophys Acta; 2012 Dec; 1824(12):1374-81. PubMed ID: 22824487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The crystal structure of the BMP-2:BMPR-IA complex and the generation of BMP-2 antagonists.
    Nickel J; Dreyer MK; Kirsch T; Sebald W
    J Bone Joint Surg Am; 2001; 83-A Suppl 1(Pt 1):S7-14. PubMed ID: 11263668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor.
    Weber D; Kotzsch A; Nickel J; Harth S; Seher A; Mueller U; Sebald W; Mueller TD
    BMC Struct Biol; 2007 Feb; 7():6. PubMed ID: 17295905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone morphogenetic proteins.
    Chen D; Zhao M; Mundy GR
    Growth Factors; 2004 Dec; 22(4):233-41. PubMed ID: 15621726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis and identification of the Grem2 heparin/heparan sulfate-binding motif.
    Kattamuri C; Nolan K; Thompson TB
    Biochem J; 2017 Mar; 474(7):1093-1107. PubMed ID: 28104757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structure of the BMP-2-BRIA ectodomain complex.
    Kirsch T; Sebald W; Dreyer MK
    Nat Struct Biol; 2000 Jun; 7(6):492-6. PubMed ID: 10881198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virtual screening and selection of drug-like compounds to block noggin interaction with bone morphogenetic proteins.
    Ahmed S; Metpally RP; Sangadala S; Reddy BV
    J Mol Graph Model; 2010 Apr; 28(7):670-82. PubMed ID: 20137990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Range Communication Network in the Type 1B Bone Morphogenetic Protein Receptor.
    Evangelista W; Yeh LC; Gmyrek A; Lee JC; Lee JC
    Biochemistry; 2015 Dec; 54(48):7079-88. PubMed ID: 26562759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of bone morphogenetic protein complexes to heparin/heparan sulfate glycosaminoglycans in bioactive conformation.
    Spanou CES; Wohl AP; Doherr S; Correns A; Sonntag N; Lütke S; Mörgelin M; Imhof T; Gebauer JM; Baumann U; Grobe K; Koch M; Sengle G
    FASEB J; 2023 Jan; 37(1):e22717. PubMed ID: 36563024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists.
    Rider CC; Mulloy B
    Biochem J; 2010 Jul; 429(1):1-12. PubMed ID: 20545624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping the heparin-binding site of the BMP antagonist gremlin by site-directed mutagenesis based on predictive modelling.
    Tatsinkam AJ; Mulloy B; Rider CC
    Biochem J; 2015 Aug; 470(1):53-64. PubMed ID: 26251446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure of the Alk1 extracellular domain and characterization of its bone morphogenetic protein (BMP) binding properties.
    Mahlawat P; Ilangovan U; Biswas T; Sun LZ; Hinck AP
    Biochemistry; 2012 Aug; 51(32):6328-41. PubMed ID: 22799562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity.
    Ruppert R; Hoffmann E; Sebald W
    Eur J Biochem; 1996 Apr; 237(1):295-302. PubMed ID: 8620887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the ligand-binding site of the BMP type IA receptor for BMP-4.
    Hatta T; Konishi H; Katoh E; Natsume T; Ueno N; Kobayashi Y; Yamazaki T
    Biopolymers; 2000; 55(5):399-406. PubMed ID: 11241215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type I receptor binding of bone morphogenetic protein 6 is dependent on N-glycosylation of the ligand.
    Saremba S; Nickel J; Seher A; Kotzsch A; Sebald W; Mueller TD
    FEBS J; 2008 Jan; 275(1):172-83. PubMed ID: 18070108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II.
    Kirsch T; Nickel J; Sebald W
    EMBO J; 2000 Jul; 19(13):3314-24. PubMed ID: 10880444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure analysis reveals how the Chordin family member crossveinless 2 blocks BMP-2 receptor binding.
    Zhang JL; Qiu LY; Kotzsch A; Weidauer S; Patterson L; Hammerschmidt M; Sebald W; Mueller TD
    Dev Cell; 2008 May; 14(5):739-50. PubMed ID: 18477456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BMP-2 and BMP-9 binding specificities with ALK-3 in aqueous solution with dynamics.
    Coskuner O; Uversky VN
    J Mol Graph Model; 2017 Oct; 77():181-188. PubMed ID: 28869862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structure of human bone morphogenetic protein-2 at 2.7 A resolution.
    Scheufler C; Sebald W; Hülsmeyer M
    J Mol Biol; 1999 Mar; 287(1):103-15. PubMed ID: 10074410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a core domain within the proregion of bone morphogenetic proteins that interacts with the dimeric, mature domain.
    Kuhfahl S; Hauburger A; Thieme T; Groppe J; Ihling C; Tomic S; Schutkowski M; Sinz A; Schwarz E
    Biochem Biophys Res Commun; 2011 May; 408(2):300-5. PubMed ID: 21510924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.